Tapan M Kadia
M.D. Anderson Cancer Center
Emerging Leaders
not ranked
Current Leaders
#3843 pts
All-Time Leaders
#7852 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2005. 10 trials as lead/chair. How it works →
Trials led — by scientific impact
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
Phase 2RecruitingM.D. Anderson Cancer Center
15
impact
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)
Phase 2RecruitingM.D. Anderson Cancer Center
12
impact
Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
Phase 1RecruitingM.D. Anderson Cancer Center
10
impact
Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML
Phase 2RecruitingM.D. Anderson Cancer Center
10
impact
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
Phase 2RecruitingM.D. Anderson Cancer Center
2
impact
Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
Phase 1ActiveCellenkos, Inc.
1
impact
PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse
Phase 2CompletedM.D. Anderson Cancer Center
1
impact
Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL)
Phase 1CompletedM.D. Anderson Cancer Center
1
impact
Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Phase 2ActiveM.D. Anderson Cancer Center
0
impact
Phase I Study of Tegavivint (BC-2059) in Patients With Relapsed and Refractory Leukemias
Phase 1ActiveM.D. Anderson Cancer Center
0
impact
Phase Ib/II Study of Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Uproleselan Plus Cladribine Plus LDAC in Patients With Treated Secondary AML (TS-AML)
Phase 1CompletedM.D. Anderson Cancer Center
0
impact
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients with Relapsed or Refractory Leukemia
Phase 1TerminatedM.D. Anderson Cancer Center
0
impact
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies
Phase 1ActiveM.D. Anderson Cancer Center
0
impact
Phase I Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory Leukemias
Phase 1ActiveM.D. Anderson Cancer Center
0
impact
Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Phase 2CompletedM.D. Anderson Cancer Center
0
impact